Marker Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a significant reduction in operating expenses and net losses compared to the same period in 2025. The company recorded total operating expenses of $2.6 million for the three months ended June 30, 2026, a decrease of 49% from $5.1 million in the prior year. This reduction was primarily driven by a 65% decline in research and development expenses, which fell to $1.5 million from $4.2 million, attributed to decreased clinical trial and consulting costs. General and administrative expenses increased by 21% to $1.1 million, mainly due to higher headcount-related expenses.
For the six months ended June 30, 2026, Marker Therapeutics reported a net loss of $5.0 million, down from $8.5 million in the same period of 2025, reflecting a 41% improvement. The company’s total revenue, primarily from grant income, was $1.4 million for the first half of 2026, compared to $1.2 million in the previous year. Grant income for the second quarter was $681,579, a decrease from $861,184 in the same quarter of 2025, while interest income remained stable at approximately $112,558.
Marker Therapeutics continues to focus on its clinical-stage immuno-oncology products, particularly its Multi-Antigen Recognizing (MAR)-T cell technology. The company has received various grants to support its clinical investigations, including a recent $4.2 million grant from the U.S. Department of War for the investigation of MT-601 in relapsed/refractory large B-cell lymphoma. As of June 30, 2026, the company had cash, cash equivalents, and restricted cash totaling approximately $11.9 million, down from $17.0 million at the end of 2025.
The company’s working capital also decreased to $12.2 million from $16.8 million at the end of the previous fiscal year. Marker Therapeutics anticipates that it will be able to fund its operating expenses and capital requirements into the second quarter of 2027, assuming no additional grant funds are received. However, the company has expressed concerns regarding its ability to continue as a going concern, given its reliance on grant income and the absence of recurring revenues from product sales.
Looking ahead, Marker Therapeutics plans to continue its research and development efforts while considering raising additional capital through equity or debt financing. The company aims to secure further grant funding to support its ongoing clinical trials and operational needs. Despite the challenges, Marker Therapeutics remains committed to advancing its product candidates and exploring strategic partnerships to enhance its market position in the immuno-oncology sector.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing non-engineered T cell therapies targeting multiple tumor antigens. Its proprietary MAR-T platform aims to treat hematological malignancies and solid tumors by expanding natural tumor-specific T cells, minimizing tumor escape and adverse effects. The company’s products include autologous and off-the-shelf therapies, with a focus on lymphoma, pancreatic cancer, AML, and MDS, leveraging broad-spectrum, cost-effective immunotherapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov